DENMARK

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190

OptimUM-10 – Darovasertib before treatment for primary uveal melanoma Phase: Phase 3Trial ID: NCT07015190Treatment: DarovasertibStage: Primary uveal melanoma – the cancer must not have spread to other parts of the bodyUK locations: University College London Hospital and The Clatterbridge Cancer Centre, Liverpool What is this trial looking at? OptimUM-10 is investigating whether giving a drug called darovasertib before the usual treatment

Neoadjuvant Darovasertib in Primary Uveal Melanoma – NCT07015190 Read More »

Study of RP-3500, Camonsertib, in Advanced Solid Tumors – NCT04497116

This Phase 1/2a study, known as the TRESR Study, is investigating the safety, how the body processes and responds to the drug (pharmacokinetics and pharmacodynamics), and the early effectiveness of RP-3500 (camonsertib) in treating advanced solid tumours with specific genetic mutations. RP-3500 will be tested both on its own and in combination with talazoparib (a

Study of RP-3500, Camonsertib, in Advanced Solid Tumors – NCT04497116 Read More »